- ISIN
- US3159184742
- Issuer
- Fidelity
- Inception Date
- Dec 27, 2000
- Category
- Health & Biotech Equities
- Min. Investment
- $0
- Distribution Policy
- Distributing
- Asset Class
- Equity
- Asset Class Size
- Mid-Cap
- Asset Class Style
- Growth
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
FBTCX Performance Chart
Fidelity Advisor Biotechnology Fund Class C (FBTCX) is up 6.2% since the beginning of the year. FBTCX is currently trading at $30 per share. Investors who bought $1,000 worth of FBTCX shares 5 years ago would now be looking at an investment worth $1,426.
Loading charts...
Returns By Period
Fidelity Advisor Biotechnology Fund Class C (FBTCX) has returned 6.20% so far this year and 54.71% over the past 12 months. Over the last ten years, FBTCX has returned 10.73% per year, falling short of the S&P 500 Index benchmark, which averaged 13.88% annually.
Fidelity Advisor Biotechnology Fund Class C
- 1D
- 0.03%
- 1M
- 2.80%
- YTD
- 6.20%
- 6M
- 3.33%
- 1Y
- 54.71%
- 3Y*
- 15.97%
- 5Y*
- 7.36%
- 10Y*
- 10.73%
Benchmark (S&P 500 Index)
- 1D
- -0.37%
- 1M
- -0.01%
- YTD
- 9.16%
- 6M
- 8.64%
- 1Y
- 25.22%
- 3Y*
- 19.78%
- 5Y*
- 11.99%
- 10Y*
- 13.88%
FBTCX Monthly Returns History
Based on dividend-adjusted daily data since Dec 27, 2000, FBTCX's average daily return is +0.04%, while the average monthly return is +0.79%. At this rate, an investment would double in approximately 7.3 years.
Historically, 60% of months were positive and 40% were negative. The best month was Dec 2023 with a return of +19.4%, while the worst month was Jan 2016 at -26.6%. The longest winning streak lasted 8 consecutive months, and the longest losing streak was 6 months.
On a daily basis, FBTCX closed higher 50% of trading days. The best single day was Oct 13, 2008 with a return of +12.5%, while the worst single day was Mar 16, 2020 at -11.8%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 1.36% | 2.10% | -1.35% | 1.98% | 0.47% | 1.53% | 6.20% | ||||||
| 2025 | 0.90% | -0.71% | -5.21% | 0.55% | -3.28% | 3.55% | 8.04% | 5.83% | 10.85% | 8.50% | 10.54% | -4.74% | 38.48% |
| 2024 | 4.14% | 6.48% | 1.85% | -8.98% | 1.63% | 4.41% | 7.80% | 2.97% | 0.46% | 0.42% | -6.21% | -14.45% | -2.00% |
| 2023 | 1.07% | -3.64% | -2.41% | 3.23% | 0.26% | 0.42% | 2.17% | -3.04% | -4.18% | -5.72% | 4.10% | 19.38% | 9.86% |
| 2022 | -12.79% | 0.21% | 4.75% | -13.21% | -6.23% | 5.45% | 2.61% | 8.40% | -1.98% | 5.40% | 1.60% | -0.41% | -8.64% |
| 2021 | 0.47% | 0.57% | -4.75% | 1.34% | -4.95% | 5.48% | -1.92% | 8.59% | -5.12% | 1.16% | -6.34% | 2.84% | -3.72% |
Benchmark Metrics
Fidelity Advisor Biotechnology Fund Class C has an annualized alpha of 2.56%, beta of 0.92, and R2 of 0.45 versus S&P 500 Index. Calculated based on daily prices since December 27, 2000.
- R2 of 0.45 means the benchmark explains less than half of this fund's behavior - treat beta with caution or consider switching to a more representative benchmark.
- Alpha
- 2.56%
- Beta
- 0.92
- R²
- 0.45
- Upside Capture
- 98.52%
- Downside Capture
- 97.69%
Expense Ratio
FBTCX has a high expense ratio of 1.75%, indicating above-average management fees.
Return for Risk
Risk / Return Rank
FBTCX ranks 80 for risk / return — in the top 80% of mutual funds on our site. This means strong returns relative to risk — exactly what professional investors look for. Well-suited for investors who want to maximize return per unit of risk.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for Fidelity Advisor Biotechnology Fund Class C (FBTCX) and compare them to S&P 500 Index.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| FBTCX | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | +0.41 | ||
| Sortino ratioReturn per unit of downside risk | +0.51 | ||
| Omega ratioGain probability vs. loss probability | 1.39 | 1.37 | +0.02 |
| Calmar ratioReturn relative to maximum drawdown | 6.11 | 2.78 | +3.32 |
| Martin ratioReturn relative to average drawdown | 16.73 | 12.44 | +4.29 |
Dividends
Dividend History
Fidelity Advisor Biotechnology Fund Class C provided a 1.58% dividend yield over the last twelve months, with an annual payout of $0.48 per share.
| Period | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend | $0.48 | $0.48 | $0.00 | $0.00 | $0.00 | $5.25 | $2.73 | $1.85 | $0.59 | $0.00 | $0.00 | $1.32 |
Dividend yield | 1.58% | 1.68% | 0.00% | 0.00% | 0.00% | 24.50% | 9.78% | 7.92% | 2.92% | 0.00% | 0.00% | 5.73% |
Monthly Dividends
The table displays the monthly dividend distributions for Fidelity Advisor Biotechnology Fund Class C. The dividends shown in the table have been adjusted to account for any splits that may have occurred.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | ||||||
| 2025 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.48 | $0.48 |
| 2024 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| 2023 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| 2022 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| 2021 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.01 | $0.00 | $0.00 | $0.00 | $0.00 | $5.24 | $5.25 |
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the Fidelity Advisor Biotechnology Fund Class C. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Fidelity Advisor Biotechnology Fund Class C was 64.04%, occurring on Jul 10, 2002. Recovery took 2410 trading sessions.
The current Fidelity Advisor Biotechnology Fund Class C drawdown is 2.28%.
Related event | Drawdown | Fall | Recovery | Underwater |
|---|---|---|---|---|
Dot-com crash2000–2002 | -64.04%Jul 2002 | 1y 6mo | 9y 6mo | 11y 1moDec 2000 - Feb 2012 |
2016 bear market2016 | -45.38%Feb 2016 | 6mo 26d | 4y 3mo | 4y 9moJul 2015 - May 2020 |
Bear market2022 | -39.37%Jun 2022 | 1y 4mo | 1y 8mo | 3y 18dFeb 2021 - Feb 2024 |
2025 selloff2025 | -37.26%Apr 2025 | 4mo 28d | 6mo 10d | 11mo 8dNov 2024 - Oct 2025 |
2014 bear market2014 | -24.40%Apr 2014 | 1mo 17d | 6mo 13d | 8moFeb 2014 - Oct 2014 |
Drawdown Indicators
| FBTCX | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -64.04% | -56.78% | -7.26% |
Max Drawdown (1Y)Largest decline over 1 year | -9.04% | -9.10% | +0.06% |
Max Drawdown (3Y)Largest decline over 3 years | -37.26% | -18.90% | -18.36% |
Max Drawdown (5Y)Largest decline over 5 years | -37.26% | -25.43% | -11.83% |
Max Drawdown (10Y)Largest decline over 10 years | -39.37% | -33.92% | -5.45% |
Current DrawdownCurrent decline from peak | -2.28% | -1.80% | -0.48% |
Average DrawdownAverage peak-to-trough decline | -23.04% | -10.71% | -12.33% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 3.29% | 2.03% | +1.26% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Build a portfolio with FBTCX
Add Fidelity Advisor Biotechnology Fund Class C to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with FBTCX